Infectious Agents and Cancer is affiliated with the African Organisation for Research & Training In Cancer (AORTIC)
Articles
Page 17 of 21
-
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A86
-
Upregulation of angiopoietin-like 4 by viral G protein-coupled receptor promotes angiogenesis and vascular permeability in Kaposi’s sarcoma
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A84 -
TNFAIP3(A20) genetic alterations in AIDS-related lymphomas
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A82 -
The use of high-dose azidothymidine in combination with chemotherapy upfront is an effective treatment approach for gamma-herpes virus-related non-Hodgkin’s lymphomas
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A81 -
The KAART Trial: a randomized controlled trial of HAART compared to the combination of HAART and \chemotherapy in treatment-naïve patients with HIV-associated Kaposi sarcoma (HIV-KS) in KwaZulu-Natal (KZN), South Africa
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A80 -
The impact of aging on cancer burden in people with HIV/AIDS
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A78 -
The HIV nef protein within ARL is genetically and structurally distinct from those in the brain of patients with HAD
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A77 -
The approach to individualized prediction of human papillomavirus (HPV) infection persistence/clearance in HIV-1-positive adolescent girls based on dynamics of CD4+ counts, viral load, and HAART
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A76 -
The angiogenic properties of Kaposi's sarcoma-associated herpesvirus encoded G-protein coupled receptor are reduced by flavopiridol, an inhibitor of cyclin-dependent kinase 9
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A75 -
T cell immunosenescence is associated with the presence of Kaposi’s sarcoma in antiretroviral treated human immunodeficiency virus-infected persons
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A74 -
Role of TP53 polymorphisms in sub-Saharan mucosal cancers
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A73 -
Rituximab combined with liposomal doxorubicin (R-Dox) in HIV-infected patients with severe Kaposi sarcoma-associated herpes virus (KSHV) associated multicentric Castleman disease (MCD)
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A72 -
Risk of HIV-associated Hodgkin lymphoma during the first months after initiation of combination antiretroviral therapy
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A71 -
Risk of anal cancer in HIV-infected patients and HIV-uninfected controls in North America
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A70 -
Relationship between salivary shedding and seropositivity for Kaposi’s sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV) among South African children and adults: insights on why EBV infection is ubiquitous and KSHV is not
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A69 -
Reasons for not adhering to cervical cancer screening guidelines and HPV knowledge among HIV indeterminate midlife women (50-64 years old) whose last Pap test was >6 years ago
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A68 -
Progression of cervical neoplasia in HIV-seropositive women with and without antiretroviral therapy in Johannesburg, South Africa
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A67 -
Prevalence of HIV-associated malignancies among PLWHAs accessing HIV services in Abia State, Nigeria
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A65 -
Pooled analysis of AIDS Malignancy Consortium (AMC) trials evaluating rituximab plus either CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin’s lymphoma
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A63 -
Phase II AIDS Malignancy Consortium (AMC) trial of topical halofuginone in AIDS-associated Kaposi’s sarcoma (KS): clinical and biological effects using a novel intra-patient control design
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A62 -
Phase II AIDS Malignancy Consortium (AMC) trial of imatinib in AIDS-associated Kaposi’s sarcoma (KS)
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A61 -
Phase IIA trial of 1% topical cidofovir for treatment of high-grade perianal squamous intraepithelial neoplasia in HIV-infected men and women (AMC046)
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A60 -
Persistence of anal squamous intraepithelial lesions and anal HPV infection in HIV-infected patientsdespite immune restoration under cART
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A59 -
Mortality after cancer diagnosis among HIV-infected individuals in the CFAR Network of Integrated Clinical Systems (CNICS)
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A56 -
Malignant lymphoma incidence and HIV-related lymphoma subtypes in the Western Cape of South Africa, 2002-2009
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A53 -
Liver cancers and other hepatic disease from the Adult/Adolescent Spectrum of HIV-related Diseases (ASD) Project
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A51 -
KSHV-mediated ROS induction defines novel therapeutic targets in Kaposi's sarcoma
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A49 -
KSHV activation, human and viral IL-6 production, and other cytokine dysregulation: Association with the symptomatology of KSHV-associated multicentric Castleman's disease
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A47 -
Kaposi’s sarcoma-associated herpesvirus (KSHV) serum DNA not associated with subsequent non-Hodgkin’s lymphoma (NHL) risk
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A44 -
Integrative proteomics and genomics supports a role for interferon gamma in the pathogenesis of Kaposi sarcoma and finds multiple candidate diagnostic proteins for early detection or prevention
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A42 -
Initial experience with topical fluorouracil (5-FU) for treatment of anal intraepithelial neoplasia (AIN) in HIV-positive patients
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A41 -
Inhibition of KSHV-associated lymphoma engraftment in SCID mouse by morpholino oligomers
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A40 -
Immunoglobulin abnormalities and monoclonal gammopathy of undetermined significance in uninfected and HIV-infected men
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A38 -
Human herpesvirus type 8 variants in Kaposi's sarcoma before and after AIDS era
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A37 -
Hsp90 is a viable therapeutic target in the treatment of KSHV-associated primary effusion lymphoma
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A36 -
HPV genotype and EGFR activation in conjunctival carcinoma among HIV patients in East Africa
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A35 -
HIV-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence, outcome, and evolution of CD4+ T cell lymphocytes
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A34 -
HIV-associated primary lung cancer (LC) in the era of highly active antiretroviral therapy (HAART): a multi-institutional collaboration
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A32 -
HAART and response to therapy improve quality of life (QOL) of African patients with advanced HIV-associated Kaposi’s sarcoma (HIV-KS): a prospective analysis of QOL in the KAART trial
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A30 -
Epstein-Barr virus (EBV)-associated miRNAs are important for the maintenance of EBV transformed B cells
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A28 -
Epidemiology of malignancies in HIV patients at Kamuzu Central Hospital in Lilongwe, Malawi
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A26 -
Elevated serum levels of heat shock protein 70 precede the development of AIDS-non-Hodgkin lymphoma in carriers of the common and highly conserved HLA-B8-DR3 haplotype
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A25 -
Elevated serum levels of CXCL13 precede HIV-associated non-Hodgkin’s lymphoma
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A24 -
Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A12 -
Characterization of lytic human herpesvirus-8 gene expression in Kaposi sarcoma tumor tissue and its clinical correlates
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A11 -
Challenges in integrating cervical cancer screening in HIV care clinics in West Africa: a pilot study in Abidjan, Côte d’Ivoire
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A10 -
Cervical cancer epidemiology among HIV-infected women in North America
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A9 -
A higher proportion of squamous intraepithelial lesion of the cervix in symptomatic HIV-infected women at a tertiary health center in Tanzania
Citation: Infectious Agents and Cancer 2010 5(Suppl 1):A1 -
Conserved mutation of Epstein-Barr virus-encoded BamHI-A Rightward Frame-1 (BARF1) gene in Indonesian nasopharyngeal carcinoma
BamHI-A rightward frame-1 (BARF1) is a carcinoma-specific Epstein-Barr virus (EBV) encoded oncogene. Here we describe the BARF1 sequence diversity in nasopharyngeal carcinoma (NPC), other EBV-related diseases ...
Citation: Infectious Agents and Cancer 2010 5:16 -
Comparison of human papillomavirus detection between freshly frozen tissue and paraffin embedded tissue of invasive cervical cancer
Human Papillomavirus (HPV) detection results comparing paraffin embedded cervical tissue and other cervical specimens have been done with varying degrees of agreement. However, studies comparing freshly frozen...
Citation: Infectious Agents and Cancer 2010 5:15
-
Affiliated with
-
- Editorial Board
- Manuscript editing services
- Instructions for Editors
- Editors' Profile
- Sign up for article alerts and news from this journal
Follow
Annual Journal Metrics
-
Citation Impact
3.698 - 2-year Impact Factor (2021)
3.572 - 5-year Impact Factor (2021)
1.03 - Source Normalized Impact per Paper (SNIP)
0.774 - SCImago Journal Rank (SJR)Speed
24 days to first decision for all manuscripts (Median)
46 days to first decision for reviewed manuscripts only (Median)Usage
413,662 Downloads (2021)
350 Altmetric mentions (2021)
What is trending?
Click here to see which articles published in Infectious Agents and Cancer have been shared the most in the past three months.